# Altimmune share price today (Altimmune, Inc., ALT)

> Altimmune, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ALT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/alt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $2.12 (−48.4% in a year)
- Revenue (Dec 2025): $26.0 K
- Profit (Dec 2025), incl. one-off: −$27.4 M (one-off item, see below)
- ROE: −39%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Altimmune share price today? Altimmune, Inc.'s share price was $2.12 at the close on 4 November 2026. It has been falling for 39 weeks. That is 34.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $6, and at that close it sat 2% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running. Over the last 9.5 years the share price moved −99% while the S&P 500 moved +207%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Altimmune pay? Altimmune, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Altimmune on? Altimmune is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Altimmune profitable? Altimmune, Inc. posted a net loss of $27.4 M in the Dec 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $88.1 M. That loss is 1,05,223.1% of the quarter's revenue. The same quarter a year earlier lost $23.2 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$27.4 M it is bigger than the quarter's whole revenue of $26.0 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,11,126.9% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Altimmune make, and is it growing? Altimmune, Inc. reported $26.0 K of revenue in the Dec 2025 quarter, +420.0% on the same quarter a year earlier. Over 4 years it has grown −68.9% a year on average. The last full year, FY25, came in at $41.0 K. The last four reported quarters add to $41.0 K. FY25 revenue was $41.0 K, +105.0% on the year before. Recent pace: the last four quarters grew +105.0% on average, against −68.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +105.0%, against −69.0% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Altimmune keep? Altimmune, Inc.'s sales have fallen to very little: FY25 revenue was $41.0 K, against $4.4 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Altimmune's profit turning into cash? Altimmune, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $67.5 M of cash, against −$88.1 M of profit. After $11.0 K of spending on assets, free cash was −$67.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Altimmune's cash go? Altimmune, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $184 K on assets over the last 3 years. Averaged over those years that is 149.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $184 K over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Altimmune's P/E ratio, and how does it compare with its own history? Altimmune, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Altimmune, Inc. at 10,058.0× its FY25 revenue of $41.0 K. The P/E comes back here once profit turns positive. ## Is the Altimmune business getting better or worse? Altimmune, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Altimmune earn on its capital? Altimmune, Inc. earned a ROE of −39% in FY25. That is up from a low of −77% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −18%, a number that says nothing useful about the business. ## Does Altimmune have too much debt? Altimmune, Inc. has total debt of $36.0 M against shareholder equity of $474 M as of Jun 2026, so its debt is 0.08× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.16 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Altimmune shareholding pattern? 25.7% of Altimmune, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 10.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Altimmune from balance-sheet trouble? For Altimmune, Inc., the Z-score is 3.35. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.35 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Altimmune rank in its industry? There is no score against its industry: Altimmune, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Altimmune compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Altimmune in size? Altimmune is the 154th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Prothena Corporation plc, Prelude Therapeutics Incorporated and Editas Medicine, Inc. Just below it: Allogene Therapeutics, Inc., Assembly Biosciences, Inc. and C4 Therapeutics, Inc. ### Biotechnology companies close in size

1. [Prothena Corporation plc](https://www.sectoralpha.in/us/stocks/prta) $431 million
2. [Prelude Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/prld) $420 million
3. [Editas Medicine, Inc.](https://www.sectoralpha.in/us/stocks/edit) $418 million
4. Altimmune, Inc. $412 million
5. [Allogene Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/allo) $411 million
6. [Assembly Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/asmb) $405 million
7. [C4 Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cccc) $384 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Repay Holdings Corporation](https://www.sectoralpha.in/us/stocks/rpay) $399 million · Software - Infrastructure
2. [G. Willi-Food International Ltd.](https://www.sectoralpha.in/us/stocks/wilc) $398 million · Food Distribution
3. Altimmune, Inc. $397 million
4. [CI&T Inc.](https://www.sectoralpha.in/us/stocks/cint) $397 million · Software - Infrastructure
5. [Portillo's Inc.](https://www.sectoralpha.in/us/stocks/ptlo) $396 million · Restaurants

## What else do people ask about Altimmune? ### What were Altimmune's latest quarterly results? Altimmune, Inc. reported revenue of $26.0 K and a net loss of $27.4 M for the Dec 2025 quarter. Earnings per share were −$0.27. The operating margin was −1,11,126.9%, 3,86,193.1 percentage points higher than a year earlier (as of 4 November 2026). ### What is Altimmune's market cap? Altimmune, Inc.'s market capitalisation is $412 M at a stock price of $2.12. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Altimmune performing? Altimmune, Inc.'s share price has been falling for 39 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Altimmune's stock price go up? This page does not forecast Altimmune, Inc.'s stock price. What it shows instead: the stock price is $2.12, and it has been falling for 39 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Altimmune story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Altimmune a stock worth studying right now? What the numbers show: Altimmune, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.